Septerna, Inc.

SEPN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023
Operating Activities
Net Income $-48.9M $-71.8M $4.2M
Depreciation & Amortization $1.6M $1.4M $800.0K
Depreciation — — —
Amortization — — —
Stock-Based Compensation $8.5M $3.2M $1.6M
Net Cash from Operating Activities $110.2M $-67.5M $-38.7M
Investing Activities
Capital Expenditures $518.0K $2.1M $2.9M
Business Acquisitions — — —
Net Cash from Investing Activities $-229.4M $-160.6M $22.1M
Financing Activities
Dividends Paid — — —
Stock Repurchases — — —
Net Cash from Financing Activities $1.7M $377.8M $74.5M
Net Change in Cash $-117.5M $149.7M $57.9M
Free Cash Flow $109.7M $-69.6M $-41.6M